. Author manuscript; available in PMC: 2013 Aug 29.

Published in final edited form as: Gynecol Oncol. 2009 Jul 3;115(1):135–137. doi: 10.1016/j.ygyno.2009.06.012

Table 2.

Statistic analysis.

154 BRCA1 mutation carriers matched sets	Univariable analysis	Multivariable analysis^a
154 BRCA1 mutation carriers matched sets	OR (95 CI) p value	OR (95 CI) p value
Tamoxifen treatment (Y/N)	0.89 (0.54–1.49) 0.66	0.78 (0.46–1.33) 0.36
Chemotherapy (Y/N)	1.39 (0.89–2.17) 0.14	1.23 (0.76–2.00) 0.40
Radiotherapy (Y/N)	1.29 (0.86–1.92) 0.22	1.32 (0.80–2.15) 0.28
Type of surgery (mastectomy)	1.17 (0.72–1.90) 0.53	1.23 (0.68–2.23) 0.49
Age at diagnosis of breast cancer (trend)	0.80 (0.72–0.91) 0.0005	0.82 (0.72–0.93) 0.002
Oral contraceptive use (Y/N)	0.85 (0.51–1.40) 0.51	0.84 (0.49–1.44) 0.52
Hormone replacement therapy (Y/N)	0.63 (0.25–1.56) 0.32	0.76 (0.29–2.00) 0.57
Parity (trend)	0.88 (0.74–1.05) 0.13	0.87 (0.72–1.04) 0.11

Multivariable analysis adjusted by oral contraceptive use (yes/no), hormone replacement treatment (yes/no), parity (trend), year of birth (trend), age at diagnosis of breast cancer (trend), radiotherapy (yes/no), chemotherapy (yes/no) and type of breast cancer surgery (mastectomy vs. lumpectomy).